Avicanna Inc. Logo

Avicanna Inc.

AVCNF

(0.8)
Stock Price

0,23 USD

-36.36% ROA

-2164.81% ROE

-4.89x PER

Market Cap.

36.496.104,81 USD

4606.94% DER

0% Yield

-24.49% NPM

Avicanna Inc. Stock Analysis

Avicanna Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Avicanna Inc. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

2 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

3 ROE

The stock's ROE indicates a negative return (-1075.4%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-67.44%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (25.53x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The company has a high debt to equity ratio (154%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Avicanna Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Avicanna Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Avicanna Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Avicanna Inc. Revenue
Year Revenue Growth
2016 0
2017 26.661 100%
2018 117.971 77.4%
2019 168.252 29.88%
2020 1.570.060 89.28%
2021 3.268.906 51.97%
2022 4.047.881 19.24%
2023 4.680.872 13.52%
2023 16.791.483 72.12%
2024 24.491.004 31.44%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Avicanna Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 0
2017 23.678 100%
2018 456.622 94.81%
2019 1.216.626 62.47%
2020 376.271 -223.34%
2021 304.312 -23.65%
2022 276.938 -9.88%
2023 431.976 35.89%
2023 330.662 -30.64%
2024 225.040 -46.93%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Avicanna Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 27.120
2017 2.481.307 98.91%
2018 7.563.724 67.19%
2019 20.526.257 63.15%
2020 15.815.811 -29.78%
2021 12.532.381 -26.2%
2022 9.605.856 -30.47%
2023 10.372.476 7.39%
2023 11.341.731 8.55%
2024 13.846.148 18.09%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Avicanna Inc. EBITDA
Year EBITDA Growth
2016 -29.832
2017 -2.519.030 98.82%
2018 -9.022.297 72.08%
2019 -21.847.722 58.7%
2020 -17.446.660 -25.23%
2021 -9.939.130 -75.54%
2022 -9.691.695 -2.55%
2023 -8.653.640 -12%
2023 -6.900.740 -25.4%
2024 -6.136.200 -12.46%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Avicanna Inc. Gross Profit
Year Gross Profit Growth
2016 0
2017 26.661 100%
2018 -54.734 148.71%
2019 92.141 159.4%
2020 -570.115 116.16%
2021 2.831.820 120.13%
2022 1.115.341 -153.9%
2023 2.351.824 52.58%
2023 6.583.005 64.27%
2024 10.788.844 38.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Avicanna Inc. Net Profit
Year Net Profit Growth
2016 -29.832
2017 -2.599.569 98.85%
2018 -7.099.061 63.38%
2019 -21.071.974 66.31%
2020 -32.861.700 35.88%
2021 -16.774.540 -95.9%
2022 -14.735.291 -13.84%
2023 -10.033.420 -46.86%
2023 -7.885.521 -27.24%
2024 -7.037.592 -12.05%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Avicanna Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 0 0%
2019 -1 100%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Avicanna Inc. Free Cashflow
Year Free Cashflow Growth
2016 -18.552
2017 -2.645.777 99.3%
2018 -8.909.157 70.3%
2019 -26.939.111 66.93%
2020 -15.427.566 -74.62%
2021 -12.452.256 -23.89%
2022 -7.502.148 -65.98%
2023 -1.961.778 -282.42%
2023 -2.068.333 5.15%
2024 -2.207.046 6.29%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Avicanna Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -18.552
2017 -2.133.418 99.13%
2018 -4.990.786 57.25%
2019 -19.449.616 74.34%
2020 -13.970.453 -39.22%
2021 -11.663.025 -19.78%
2022 -7.435.368 -56.86%
2023 -1.404.218 -429.5%
2023 -2.051.886 31.56%
2024 -2.208.527 7.09%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Avicanna Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 0
2017 512.359 100%
2018 3.918.371 86.92%
2019 7.489.495 47.68%
2020 1.457.113 -414%
2021 789.231 -84.62%
2022 66.780 -1081.84%
2023 557.560 88.02%
2023 16.447 -3290.04%
2024 -1.481 1210.53%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Avicanna Inc. Equity
Year Equity Growth
2016 -29.762
2017 841.067 103.54%
2018 26.379.675 96.81%
2019 29.875.781 11.7%
2020 13.909.830 -114.78%
2021 6.908.022 -101.36%
2022 3.458.651 -99.73%
2023 7.972.110 56.62%
2023 1.172.900 -579.69%
2024 7.959.133 85.26%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Avicanna Inc. Assets
Year Assets Growth
2016 93.001
2017 2.117.470 95.61%
2018 28.181.001 92.49%
2019 45.164.282 37.6%
2020 30.155.561 -49.77%
2021 22.301.614 -35.22%
2022 17.619.231 -26.58%
2023 21.971.108 19.81%
2023 17.850.029 -23.09%
2024 19.366.490 7.83%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Avicanna Inc. Liabilities
Year Liabilities Growth
2016 122.763
2017 1.276.403 90.38%
2018 1.801.326 29.14%
2019 15.288.501 88.22%
2020 16.245.731 5.89%
2021 15.393.592 -5.54%
2022 14.160.580 -8.71%
2023 13.998.997 -1.15%
2023 12.957.725 -8.04%
2024 11.407.357 -13.59%

Avicanna Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.27
Net Income per Share
-0.07
Price to Earning Ratio
-4.89x
Price To Sales Ratio
1.47x
POCF Ratio
-119.79
PFCF Ratio
-61.07
Price to Book Ratio
941.02
EV to Sales
1.51
EV Over EBITDA
-7.6
EV to Operating CashFlow
-140.67
EV to FreeCashFlow
-62.88
Earnings Yield
-0.2
FreeCashFlow Yield
-0.02
Market Cap
0,04 Bil.
Enterprise Value
0,04 Bil.
Graham Number
0.02
Graham NetNet
-0.08

Income Statement Metrics

Net Income per Share
-0.07
Income Quality
0.04
ROE
-60.14
Return On Assets
-0.3
Return On Capital Employed
-0.48
Net Income per EBT
0.9
EBT Per Ebit
1.31
Ebit per Revenue
-0.21
Effective Tax Rate
0.1

Margins

Sales, General, & Administrative to Revenue
0.49
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
0.47
Operating Profit Margin
-0.21
Pretax Profit Margin
-0.27
Net Profit Margin
-0.24

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
-1.24
Capex to Revenue
0.01
Capex to Depreciation
0.36
Return on Invested Capital
-3.31
Return on Tangible Assets
-0.36
Days Sales Outstanding
32.13
Days Payables Outstanding
166.28
Days of Inventory on Hand
90.08
Receivables Turnover
11.36
Payables Turnover
2.2
Inventory Turnover
4.05
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,08
Tangible Book Value per Share
0.07
Shareholders Equity per Share
0
Interest Debt per Share
0.02
Debt to Equity
46.07
Debt to Assets
0.08
Net Debt to EBITDA
-0.22
Current Ratio
0.69
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
9717581
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
3816846
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Avicanna Inc. Dividends
Year Dividends Growth

Avicanna Inc. Profile

About Avicanna Inc.

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

CEO
Mr. Aras Azadian B.Econ, Mba
Employee
87
Address
480 University Avenue
Toronto, M5G 1V2

Avicanna Inc. Executives & BODs

Avicanna Inc. Executives & BODs
# Name Age
1 Mr. Enric Pujol
Vice President of People
70
2 Mr. Arash Moghani MBA
Executive Vice President of Operations & Technology
70
3 Dr. Carlos Enrique Maldonado Muete
SVice President of Clinical Development
70
4 Ms. Ingrid Diaz
Vice President, Assistant General Counsel & Corporate Compliance Officer
70
5 Dr. Karolina Urban
Executive Vice President of Scientific & Medical Affairs
70
6 Mr. Aras Azadian B.Econ, Mba
Co-Founder, Chief Executive Officer & Director
70
7 Mr. Phillip Cardella C.A., CPA
Chief Financial Officer
70
8 Ms. Ivana Maric
Executive Vice President of Marketing
70
9 Mr. Stephen Kim
Chief Legal Officer & General Counsel of Avicanna USA Inc.
70

Avicanna Inc. Competitors